STUDIES ON PATHOLOGY OF ADENINE INDUCED CHRONIC KIDNEY DISEASE AND AMELIORATIVE EFFECTS OF GOKSHURADI GUGGULU IN MALE WISTAR RATS
Loading...
Date
2024
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
KARNATAKA VETERINARY, ANIMAL AND FISHERIES SCIENCES UNIVERSITY, BIDAR
Abstract
The present study was undertaken to establish the adenine induced chronic kidney disease (CKD) model in rats and to evaluate the nephroprotective efficacy of polyherbal Gokshuradi Guggulu (GG) in this model. The study involved 6 groups of 8 male wistar rats each viz; Group I: normal control gavaged with 0.2 percent carboxy methyl cellulose (CMC), Group II: CKD control, treatment Groups III, IV, V & VI gavaged with adenine @ 50 mg/kg for 28 days, further from day 7 to 35th day of study, treatment Groups III, IV, V gavaged with GG @ 100 mg/kg, 200 mg/kg, and 400 mg/kg respectively and Group VI with vitamin E, selenium, and prednisolone (200 mg/kg, 400 μg/kg and 5 mg/kg respectively). Adenine successfully induced CKD in the rats of Group II as evidenced by the clinical signs, elevated Creatinine and BUN and diffuse gross and histopathological changes in the kidneys. Treatment Groups III and IV showed no improvement in adenine induced CKD. There was a mild degree of improvement in serological and haematological parameters and renal histology with decreased interstitial inflammation and fibrosis in rats of Group V when compared with that of Group II. While rats of treatment Group VI, significantly alleviated the adenine induced CKD, marked by significant improvement in renal serological and hematological parameters, gross and histological parameters, but not on par with normal control. The present study indicated that CKD can be successfully induced in male Wistar rats by gavaging adenine at 50 mg/kg for 28 days. The study revealed that Gokshuradi Guggulu at 400 mg/kg had mild nephroprotective effect and ameliorated the adenine-induced CKD changes only to a certain extent. Further preclinical studies by prolonging the duration of the GG treatment as well as enhancing the bioavailability of the active constituents are required to evaluate its usage.